Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 9/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733018 | 1.00 | AHCY (0.66) | AHCYFGFR1SLC22A6CYP3A4ADORA2A | |
| SCHEMBL11378379 | 1.00 | AHCY (0.66) | AHCYFGFR1SLC22A6CYP3A4ADORA2A | |
| Butane SCHEMBL1731733 | 0.95 | AHCY (0.60) | AHCYFGFR1SLC22A6CYP3A4ADORA2A | |
| SCHEMBL11307115 | 0.90 | AHCY (0.63) | AHCYFGFR1SLC22A6CYP3A4ADORA2A | |
| SCHEMBL5584021 | 0.86 | AHCY (0.61) | AHCYFGFR1SLC22A6ADORA2AADORA1 | |
| SCHEMBL11383312 | 0.82 | FGFR1 (0.53) | AHCYFGFR1SLC22A6CYP3A4ENPP1 | |
| SCHEMBL9285391 | 0.81 | FGFR1 (0.62) | AHCYFGFR1SLC22A6CYP3A4ADORA2A | |
| SCHEMBL6158904 | 0.78 | AHCY (0.76) | AHCYADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL28742775 | 0.78 | FGFR1 (0.65) | AHCYFGFR1SLC22A6CYP3A4ADORA2A | |
| SCHEMBL9563483 | 0.78 | AHCY (0.60) | AHCYFGFR1SLC22A6CYP3A4ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142792-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2019-05-16 | — | — | US | claimed |
| US-20170035726-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2017-02-09 | — | — | US | claimed |
| US-20150011488-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2015-01-08 | — | — | US | claimed |
| US-20110218241-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2011-09-08 | — | — | US | claimed |
| US-8222257-B2 | Phosphono-pent-2-en-1-yl nucleosides and analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-17 | — | — | US | disclosed |
| EP-1866319-B1 | PHOSPHONO-PENT-2-EN-1-YL NUCLEOSIDES AND ANALOGS | UNIV CALIFORNIA (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20090215726-A1 | Phosphono-Pent-2-en-1-yl Nucleosides and Analogs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011488-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | AHCY 816/4885FGFR1 4771/4885SLC22A6 4586/4885 |
| US-20170035726-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | AHCY 816/4885FGFR1 4771/4885SLC22A6 4586/4885 |
| US-20090215726-A1 | Phosphono-Pent-2-en-1-yl Nucleosides and Analogs | PNP, TYMP, ENPP1 | AHCY 2934/4885FGFR1 2327/4885SLC22A6 3430/4885 |
| US-20110218241-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, MGMT | AHCY 570/4885FGFR1 4735/4885SLC22A6 4401/4885 |
| US-20190142792-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | AHCY 816/4885FGFR1 4771/4885SLC22A6 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.